Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

Archive ouverte

Kuksa, L. | Andrejak, C. | Haecker, B. | Bothamley, G. | Calcagno, A. | Cirillo, D.M. | Duarte, R. | Fatima, R. | Ferlazzo, G. | Guglielmetti, L. | Günther, G. | Hewison, C. | Horsburgh, C.R. | Jäger, T. | Kalancha, Y. | Otto-Knapp, R. | Kranzer, K. | Lillebaek, T. | Marks, G. | Middelkoop, K. | Motta, I. | Rabinova, V. | Sommerfeld, P. | Tattevin, P. | Lange, C.

Edité par CCSD -

International audience. Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approved label for pretomanid restricts its use to the regimen comprising bedaquiline, pretomanid and linezolid (BPaL) and only for extensively drug-resistant-TB or multidrug-resistant TB, “when antibiotics used for the latter form of TB do not work or cause unacceptable side effects.” This restricted use implies that the older, prolonged and poorly tolerated regimens remain the recommended treatment for most cases of drug-resistant TB. The authors, representing many respiratory groups and societies, call for the label expansion of pretomanid to align with global guidelines, allowing for broader use.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion